Summary
Side effects of insulin treatment (red spots at the injection site, lipoatrophy and insulin antibody formation) are primary related to the purity and the species of the insulin preparations used in treatment. To evaluate the clinical significance of these factors daily insulin requirements were registered in 1685 protamine insulin treated cases; red spots and lipoatrophy recorded in 500 NPH insulin treated patients and insulin antibodies determined in 173 patients. 51 of the patients were treated for more than 12 months with highly purified porcine insulin (proinsulin contamination <0.5 mmol/mol). 96 patients were treated for 1–4 years with porcine NPH insulin (proinsulin contamination 12–13 mmol/mol), and most of the remaining patients have been treated with mixed porcine-bovine insulin preparations in earlier periods. It was shown that high purification of porcine NPH insulin is of importance in reducing insulin dose, lipoatrophy and insulin binding capacity of serum. Thus insulin antibodies could be demonstrated in only 3 of 51 patients after 11/2 year of treatment with highly purified porcine NPH insulin. None of these patients developed red spots at the injection site and only one patient developed a small shallow depression of the subcutaneous tissue on one thigh. The daily insulin requirement was significantly lower when compared with the insulin requirement of a porcine NPH insulin treated control group.
Article PDF
Similar content being viewed by others
References
Andersen, O.O., Brunfeldt, K., Abildgård, F.: A method for quantitative determination of insulin-antibodies in human plasma. Acta endocr. (Kbh.)69, 195–208 (1972)
Andersen, O.O.: Insulin antibody formation: I: The influence of age, sex, infections, insulin dosage and regulation of diabetes. Acta endoor. (Kbh.)71, 126–140 (1972)
Andersen, O.O.: Insulin antibody formation: II: The influence of species difference and method of administration. Acta endocr. (Kbh.)72, 33–45 (1973)
Andersen, O.O.: Unpublished results 1973
Andersen, O.O.: To be published 1974
Andreani, D., Iavicolli, M., Coletti, A., Menzinger, G.: Esperienze nel trattamento del diabete con le insuline di tipo monocomponenta (MC) e monospecie (MS). Folia endocr.25, 516–539 (1972)
Annotations: An insulin hazard? Lancet1966 II, 897–898
Berson, S.A., Yalow, R.S.: Insulin in blood and insulin antibodies. Amer. J. Med.40, 676–690 (1966)
Brunfeldt, K., Deckert, T.: The antigenic properties of pig insulin. Acta Endocr. (Kbh.)47, 353–366 (1964)
Bruni, B., D'Alberto, M., Osenda, M., Ricci, C., Turco, G.L.: Clinical Trial with Monocomponent Lente Insulin. Diabetologia9, 492–498 (1973)
Deckert, T.: Insulin Antibodies. Thesis. Munksgaard, Copenhagen, 1964
Devlin, J., Duggan, G.M.: Antibody studies in patients on mixed bovine/porcine insulins. Diabetologia5, 192–194 (1969)
Dixon, K., Exon, P.D., Hughes, H.R.: Insulin antibodies in aetiology of labile diabetes. Lancet1972 I, 343–347
Fankhauser, S., Michl, J.: Internationales Donau Symposium über Diabetes mellitus: P: 43–47, Salzburg. Ed.: A. Beringer. Wien: Wilhelm Maudrich 1973
Field, J.B.: Chronic insulin resistance. Metabolism11, 636–640 (1962)
Hagedorn, H.C., Norman Jensen, B., Krarup, N.B., Wodstrup, I.: Protamine insulinate. J. Amer. med. Ass.106, 177–180 (1936)
Hales, C.N., Randle, P.J.: Immunoassay of insulin with antibody precipitate. Biochem. J.88, 137–146 (1963)
Jorpes, J.E.: Recrystallized insulin for diabetic patients with insulin allergy. Arch. intern. Med.83, 363–371 (1949)
Korp, W., Levett, R.E.: Erfahrungen mit Monokomponenten Insulin. Wien. klin. Wschr.85, 326–330 (1973)
Krayenbühl, C.H., Rosenberg, Th.: Crystalline Protamine Insulin. Rep. Steno Hosp.1, 60–73 (1946)
Kühnau, J. Jr.: Insulinbindungskapazität des Serums bei Diabetikern mit erhöhtem Insulinbedarf. Verh. dtsch. Ges. inn. Med.74, 1133–1135 (1968)
Larsson, O.: Studies of small vessels in patients with diabetes. Acta med. scand. Suppl.183, 480 (1967)
Marble, A., White, P., Bradly, R.F., Krall, L.P.: Joslin's Diabetes Mellitus. P: 703. Lea & Fibiger, Philadelphia (1971)
Poulsen, J.E., Werner, A.U.: Immunologische Methoden zur fluoreszenzmikroskopischen und autoradiographischen Untersuchung an diabetischem und nichtdiabetischem Humangewebe. Verhandlungen des I. Internationalen Donau Symposiums über Diabetes Mellitus. Ed: A. Beringer. E. Deutsch. Wiener Medizinische Akademie Wien 1969
Renold, A.E., Winegrad, A.I., Martins, D.B.: Diabete sucré et tissue adipeux. Helv. med. Acta24, 322–327 (1957)
Schlichtkrull, J., Brange, J., Christiansen, Aa.H., Hallund, O., Heding, L.G., Jørgensen, K.H.: Clinical aspects of insulin antigenicity. Diabetes22, 649–656 (1972)
Schlichtkrull, J., Brange, J., Christiansen, Aa.H., Hallund, O., Heding, L.G., Jørgensen, K.H., Munkgaard Rasmussen, S., Sørensen, E., Vølund, Aa.: Monocomponent insulin and its clinical implications. The 5th E.F.F. Copp lecture. University of Southern California Medical Center. March 16th. 1973
Steiner, D.F., Kemmler, W., Clark, J.L., Oyer, P.E., Rubenstein, A.H.: The biosynthesis of insulin. In: Handbook of Physiology, section 7: Endocr., vol. 1: 175–198. Amer. Physiol. Soc. Wash. D.C. 1972
Watson, D., Vines, R.: Variations in the incidence of lipoatrophy using different insulin. Med. J. Aust. 1, 248–250 (1973)
Wegmüller, E., Fankhauser, S.: Die Antigenität verschiedener Depotinsulinpräparate bei Diabetikern. Helv. med. Acta50, 130 (1971)
Wehner, H., Huber, H., Kronenberg, K.H.: The Glomerular Basement Membrane of the Rabbit Kidney on Long-Term Treatment with Heterologous Insulin Preparations of Different Purity. Diabetologia9, 255–263 (1973)
Author information
Authors and Affiliations
Additional information
With the technical assistance of Hanne Richter-Olesen.
Rights and permissions
About this article
Cite this article
Deckert, T., Andersen, O.O. & Pouken, J.E. The clinical significance of highly purified pig-insulin preparations. Diabetologia 10, 703–708 (1974). https://doi.org/10.1007/BF01219531
Received:
Revised:
Issue Date:
DOI: https://doi.org/10.1007/BF01219531